KR920002631A - Class II protein of Neisseria meningitidis outer membrane with immunological carrier and enhancing properties - Google Patents

Class II protein of Neisseria meningitidis outer membrane with immunological carrier and enhancing properties Download PDF

Info

Publication number
KR920002631A
KR920002631A KR1019910012308A KR910012308A KR920002631A KR 920002631 A KR920002631 A KR 920002631A KR 1019910012308 A KR1019910012308 A KR 1019910012308A KR 910012308 A KR910012308 A KR 910012308A KR 920002631 A KR920002631 A KR 920002631A
Authority
KR
South Korea
Prior art keywords
protein
outer membrane
class
administered
neisseria meningitidis
Prior art date
Application number
KR1019910012308A
Other languages
Korean (ko)
Inventor
아이. 올리프 앨런
에이. 류 마거릿
프리드만 아더
와이. 타이 죠셉
제이. 돈넬리 죤
Original Assignee
제임스 에프. 노턴
머크 앤드 캄파니, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제임스 에프. 노턴, 머크 앤드 캄파니, 인코포레이티드 filed Critical 제임스 에프. 노턴
Publication of KR920002631A publication Critical patent/KR920002631A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

내용 없음No content

Description

면역학적 캐리어 및 강화 특성을 지닌 나이세리아 메닌자이티디스 외막의 클래스 Ⅱ 단백질Class II protein of Neisseria meningitidis outer membrane with immunological carrier and enhancing properties

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음As this is a public information case, the full text was not included.

제1도는 PRP-OMPC로 면역화한 후 일정일에 취한 혈액 샘플에서 ELISA로 측정한, PRP-DT 및 MIEP, 또는 OMPC, 또는 IAA-OMPC로 개별적으로 프라이밍된 비장 세포를 수용하는 채택성 이전 수용자의 항체 반응도이다.FIG. 1 is a diagram of the adoptive prior recipients receiving spleen cells individually primed with PRP-DT and MIEP, or OMPC, or IAA-OMPC, as measured by ELISA in blood samples taken on day after immunization with PRP-OMPC. Antibody reactivity.

제2도는 시험관내에서 수행한 MIEP의 마이토젠(mitogen)활성에 대한 림프구 증식 검정도이다.Figure 2 is a lymphocyte proliferation assay for mitogen activity of MIEP performed in vitro.

제3도는 PRP-MIEP 접합체의 마우스 및 새끼 붉은털 원숭이에서 수행한 면역원성 시험도이다.FIG. 3 is an immunogenicity test diagram performed in mice and rhesus macaques of PRP-MIEP conjugates.

Claims (15)

그람 음성균의 외막으로부터 정제된 실질적으로 순수한 형태의 단백질을 투여함을 특징으로 하여, 항원에 대한 면역 반응을 증가시키는 방법.A method of increasing the immune response to an antigen, characterized by administering a protein in substantially pure form purified from the outer membrane of Gram-negative bacteria. 제1항에 있어서, 실질적으로 순수한 형태의 나이세리아 메닌자이티디스(Neisseria meningitidis), 혈청 그룹 B의 외막의 클래스 Ⅱ 단백질을 투여하는 방법.The method of claim 1, wherein Neisseria meningitidis, class II protein of the outer membrane of serum group B, is administered in substantially pure form. 제2항에 있어서, 항원(들)을 투여하는 방법.The method of claim 2, wherein the antigen (s) are administered. 제3항에 있어서, 항원이 세균, 바이러스, 포유류 세포, 진균, 리켓치아, 알레르기원, 독 또는 독물, 합성펩타이드 및 폴리펩타이드 단편으로부터 유도되는 방법.The method of claim 3, wherein the antigen is derived from bacteria, viruses, mammalian cells, fungi, rickettsias, allergens, poisons or poisons, synthetic peptides and polypeptide fragments. 재조합 숙주 세포내에서 생성된, 그람 음성균의 외막의 재조합 단백질을 투여함을 특징으로 하여, 항원에 대한 면역 반응을 증가시키는 방법.A method for increasing the immune response to an antigen, characterized by administering a recombinant protein of the outer membrane of Gram-negative bacteria produced in a recombinant host cell. 제5항에 있어서, 재조합 숙주 세포내에서 생성된, 나이세리아 메닌자이티디스, 혈청 그룹 B의 외막의 재조합 클래스 Ⅱ 단백질을 투여하는 방법.6. The method of claim 5, wherein the recombinant class II protein of Neisseria meningitidis, the outer membrane of serum group B, produced in recombinant host cells is administered. 제6항에 있어서, 항원(들)을 투여하는 방법.The method of claim 6, wherein the antigen (s) are administered. 제7항에 있어서, 항원이 세균, 바이러스, 포유류 세포, 진균, 리켓치아, 알레르기원, 독 또는 독물, 합성 펩타이드 및 폴리펩타이드 단편으로부터 유도되는 방법.8. The method of claim 7, wherein the antigen is derived from bacteria, viruses, mammalian cells, fungi, rickettsia, allergens, poisons or poisons, synthetic peptides and polypeptide fragments. 그람 음성균의 외막으로부터 정제된 실질적으로 순수한 형태의 단백질을 투여함을 특징으로 하여, 포유류에서 사이토카인의 수준을 증가시키는 방법.A method of increasing cytokine levels in a mammal, characterized by administering a protein in substantially pure form purified from the outer membrane of Gram-negative bacteria. 제1항에 있어서, 실질적으로 순수한 형태의 나이세리아 메닌자이티디스, 혈청 그룹 B의 외막의 재조합 클래스 Ⅱ 단백질을 투여하는 방법.The method of claim 1, wherein the recombinant class II protein of Neisseria meningitidis, the outer membrane of serum group B, is administered in substantially pure form. 제1항에 있어서, 재조합 숙주 세포내에서 생성된, 나이세리아 메닌자이티디스, 혈청 그룹 B의 외막의 재조합 클래스 Ⅱ 단백질을 투여하는 방법.The method of claim 1, wherein the recombinant class II protein of Neisseria meningitidis, the outer membrane of serum group B, produced in recombinant host cells is administered. 그람 음성균의 외막으로부터 정제된 실질적으로 순수한 형태의 단백질을 투여함을 특징으로 하여, 포유류에서 인터루킨-2의 수준을 증가시키는 방법.A method of increasing the level of interleukin-2 in a mammal, characterized by administering a protein in substantially pure form purified from the outer membrane of Gram-negative bacteria. 제12항에 있어서, 재조합 숙주 세포내에서 생성된, 그람 음성군의 외막의 재조합 단백질을 투여하는 방법.The method of claim 12, wherein the recombinant protein of the outer membrane of the Gram-negative group produced in the recombinant host cell is administered. 실질적으로 순수한 형태의 나이세리아 메닌자이티디스, 혈청 그룹 B의 외막의 클래스 Ⅱ 단백질을 투여함을 특징으로 하여, 포유류에서 인터루킨-2의 수준을 증가시키는 방법.A method of increasing the level of interleukin-2 in a mammal, characterized by administering a substantially pure form of Neisseria meningitidis, class II protein of the outer membrane of serum group B. 제14항에 있어서, 재조합 숙주 세포내에서 생성된, 나이세리아 메닌자이티디스, 혈청 그룹 B의 외막의 재조합 클래스 Ⅱ 단백질을 투여하여 포유류에서 인터루킨-2의 수준을 증가시키는 방법.15. The method of claim 14, wherein the recombinant class II protein of the outer membrane of Neisseria meningitidis, serum group B, produced in recombinant host cells is administered to increase the level of interleukin-2 in the mammal. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019910012308A 1990-07-19 1991-07-19 Class II protein of Neisseria meningitidis outer membrane with immunological carrier and enhancing properties KR920002631A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US55520490A 1990-07-19 1990-07-19
US07/555,204 1990-07-19
US63945791A 1991-01-10 1991-01-10
US07/639,457 1991-01-10

Publications (1)

Publication Number Publication Date
KR920002631A true KR920002631A (en) 1992-02-28

Family

ID=27070823

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910012308A KR920002631A (en) 1990-07-19 1991-07-19 Class II protein of Neisseria meningitidis outer membrane with immunological carrier and enhancing properties

Country Status (9)

Country Link
JP (1) JPH0656690A (en)
KR (1) KR920002631A (en)
AU (1) AU8114091A (en)
CA (1) CA2047043A1 (en)
FI (1) FI913473A (en)
IL (1) IL98837A0 (en)
MX (1) MX9100272A (en)
NO (1) NO912822L (en)
PT (1) PT98381A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0010361A (en) * 1999-04-30 2003-06-10 Chiron Corp Genetic sequences of neisseria and use of these
GB0011108D0 (en) * 2000-05-08 2000-06-28 Microscience Ltd Virulence gene and protein and their use

Also Published As

Publication number Publication date
NO912822D0 (en) 1991-07-18
JPH0656690A (en) 1994-03-01
AU8114091A (en) 1992-01-23
NO912822L (en) 1992-01-20
FI913473A (en) 1992-01-20
FI913473A0 (en) 1991-07-18
CA2047043A1 (en) 1992-01-20
PT98381A (en) 1992-05-29
IL98837A0 (en) 1992-07-15
MX9100272A (en) 1992-02-28

Similar Documents

Publication Publication Date Title
Selvaggi et al. Development of antibodies to fetal calf serum with arthus-like reactions in human immunodeficiency virus–infected patients given syngeneic lymphocyte infusions
Adler et al. Cellular recognition by mouse lymphocytes in vitro: I. Definition of a new technique and results of stimulation by phytohemagglutinin and specific antigens
LoSpalluto et al. The formation of macroglobulin antibodies. I. Studies on adult humans
AU639456B2 (en) Diagnosis and treatment of insulin dependent diabetes mellitus
Katz et al. Immunological focusing by the mouse major histocompatibility complex: mouse strains confronted with distantly related lysozymes confine their attention to very few epitopes
ATE122394T1 (en) PANCREATIC ISLE CELL ANTIGENS OBTAINED BY MOLECULAR CLONING.
Mills et al. Excretions and secretions of Trichinella spiralis and their role in immunity
Trembleau et al. Early Th1 response in unprimed nonobese diabetic mice to the tyrosine phosphatase-like insulinoma-associated protein 2, an autoantigen in type 1 diabetes
Holen et al. Specific T cell lines for ovalbumin, ovomucoid, lysozyme and two OA synthetic epitopes, generated from egg allergic patients' PBMC
US5578303A (en) Diagnosis and treatment of insulin dependent diabetes mellitus
Thorne et al. Partial purification and biological properties of an eosinophil‐activating factor
Yoshida et al. Activity of migration inhibitory factor in the absence of antigen
Gabrielli et al. A retrospective study of antibodies against basement membrane antigens (type IV collagen and laminin) in patients with primary and secondary Raynaud's phenomenon
AU608413B2 (en) Mouse monoclonal antibody (5-21-3) to human immunodeficiency virus gp41 protein
KR920002631A (en) Class II protein of Neisseria meningitidis outer membrane with immunological carrier and enhancing properties
Norins et al. Globulins on NZB mouse erythrocytes
KR920002632A (en) Class II protein of Neisseria meningitidis outer membrane with immunological carrier and enhancing properties and vaccine containing the same
Bauer THE ANTIGENIC DETERMINANTS OF SEVERAL HUMAN PLASMA PROTEINS: Their Determination from the Investigation of the Cross‐Reactions between Human and Other Mammalian Plasmas
IBSEN et al. β‐MICROGLOBULIN SERUM LEVELS IN INFECTIOUS MONONUCLEOSIS IN CHILDHOOD
Iversen et al. The major internal protein, p27, of a retrovirus-like particle is expressed in blood lymphocytes from psoriatic patients
KR920002634A (en) Class II protein of Neisseria menin Zytidis outer membrane with immunological carrier and enhancing properties
Platzer et al. Identification of an immunodominant region on the isolated bovine leukaemia virus (BLV) major envelope protein gp51 by monoclonal antibodies presumably not exposed during natural BLV infection.
Piersma et al. An in vitro immune response model to determine tetanus toxoid antigen (vaccine) specific immunogenicity: Selection of sensitive assay criteria
Itaya et al. Suppression of IgE antibody formation in mice with nonspecific stimulation
Liao et al. A simple microassay for detection of antibodies to fetal calf serum and related antigens and its application to the serological definition of human tumor antigens

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid